Our core therapeutic technology (CAP-1002) is based on cardiosphere-derived cells, or CDCs, a cardiac-derived cell therapy that was first identified in the academic laboratory of Capricor’s scientific founder, Dr. Eduardo Marbán. Since the initial publication in 2007, CDCs have been the subject of over 100 peer-reviewed scientific publications and have been administered to approximately 200 human subjects across several clinical trials. CAP-1002 consists of allogeneic “off-the-shelf” cardiosphere-derived cells, or CDCs, a type of cardiac cell therapy that has been shown in pre-clinical and clinical studies to exert potent immunomodulatory activity. It is being investigated for its potential to modify the immune system’s activity to encourage cellular regeneration. The cells function by releasing exosomes that are taken up largely by macrophages and T-cells and begin a cycle of repair.

CAP-1002 has been granted orphan drug designation by the FDA for the treatment of DMD.

Completed Trials

HOPE-2 clinical trial in patients with Duchenne muscular dystrophy

HOPE Phase I/II clinical trial in patients with DMD-associated cardiomyopathy

ALLSTAR Phase II clinical trial in patients who have experienced a large heart attack


View a list of publications relating to CAP-1002.